Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 11, 2002

Arteriosclerosis, Thrombosis, and Vascular Biology. 2002
Published online before print April 11, 2002, doi: 10.1161/01.ATV.0000018304.30943.06
A more recent version of this article appeared on June 1, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/6/989    most recent
01.ATV.0000018304.30943.06v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millar, J. S.
Right arrow Articles by Rader, D. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Millar, J. S.
Right arrow Articles by Rader, D. J.
Related Collections
Right arrow Animal models of human disease
Right arrow Fibrinogen/fibrin
Right arrow Lipid and lipoprotein metabolism

Submitted on March 1, 2002
Accepted on March 15, 2002

Normal Production Rate of ApoB in LDL Receptor--Deficient Mice

John S. Millar *; Cyrille Maugeais ; Ilia V. Fuki ; and Daniel J. Rader

From the Department of Medicine, University of Pennsylvania, Philadelphia.

* To whom correspondence should be addressed. E-mail: jsmillar{at}mail.med.upenn.edu.

Abstract—The low density lipoprotein (LDL) receptor is well known for its role in mediating the removal of apolipoprotein B (apoB)-containing lipoproteins from plasma. Results from in vitro studies in primary mouse hepatocytes suggest that the LDL receptor may also have a role in the regulation of very low density lipoprotein (VLDL) production. We conducted in vivo experiments using LDLR-/-, LDLR+/-, and wild-type mice (LDLR indicates LDL receptor) in which the production rate of VLDL was measured after the injection of [35S]methionine and the lipase inhibitor Triton WR1339. Despite the fact that LDLR-/- mice had a 3.7-fold higher total cholesterol level and a 2.1-fold higher triglyceride level than those of the wild-type mice, there was no difference in the production rate of VLDL triglyceride or VLDL apoB between these groups of animals. Experiments were also conducted in apobec1-/- mice, which make only apoB-100, the form of apoB that binds to the LDL receptor. Interestingly, the apobec1-/- mice had a significantly higher production rate of apoB than did the wild-type mice. However, despite significant differences in total cholesterol and triglyceride levels, there was no difference in the production rate of total or VLDL triglyceride or VLDL apoB between LDLR-/- and LDLR+/- mice on an apobec1-/- background. These results indicate that the LDL receptor has no effect on the production rate of VLDL triglyceride or apoB in vivo in mice.


Key words: triglycerides • very low density lipoproteins • familial hypercholesterolemia • Triton WR1339 • apobec1